Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects.

PubWeight™: 1.20‹?› | Rank: Top 10%

🔗 View Article (PMID 2052525)

Published in Pharm Res on March 01, 1991

Authors

A J Coupe1, S S Davis, I R Wilding

Author Affiliations

1: Department of Pharmaceutical Sciences, University of Nottingham, U.K.

Articles citing this

Development and evaluation of oral multiple-unit and single-unit hydrophilic controlled-release systems. AAPS PharmSciTech (2000) 1.25

Physiological parameters for oral delivery and in vitro testing. Mol Pharm (2010) 1.18

Tuberculosis chemotherapy: current drug delivery approaches. Respir Res (2006) 1.11

Models for oral uptake of nanoparticles in consumer products. Toxicology (2011) 1.07

Gastric transit and small intestinal transit time and motility assessed by a magnet tracking system. BMC Gastroenterol (2011) 1.00

Modeling the fluid dynamics in a human stomach to gain insight of food digestion. J Food Sci (2010) 0.98

Effect of altered gastric emptying and gastrointestinal motility on metformin absorption. Br J Clin Pharmacol (2000) 0.89

The effects of pharmaceutical excipients on small intestinal transit. Br J Clin Pharmacol (1995) 0.83

Proof-of-concept study on the suitability of 13C-urea as a marker substance for assessment of in vivo behaviour of oral colon-targeted dosage forms. Br J Pharmacol (2009) 0.81

Colon-targeted oral drug delivery systems: design trends and approaches. AAPS PharmSciTech (2015) 0.78

The impact of vehicles on the mucoadhesive properties of orally administrated nanoparticles: a case study with chitosan-4-thiobutylamidine conjugate. AAPS PharmSciTech (2010) 0.77

Design of Chronomodulated Drug Delivery System of Valsartan: In Vitro Characterization. Indian J Pharm Sci (2015) 0.75

Absolute bioavailability and regional absorption of ticagrelor in healthy volunteers. J Drug Assess (2014) 0.75

Articles by these authors

Transit of pharmaceutical dosage forms through the small intestine. Gut (1986) 2.35

PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release (1999) 2.08

Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev (2001) 1.87

Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res (1994) 1.61

Evaluation of impotence in older men. West J Med (1985) 1.54

The preparation and characterization of poly(lactide-co-glycolide) microparticles. II. The entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique. Pharm Res (1993) 1.53

Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating. Biochem Biophys Res Commun (1991) 1.50

Heavy metals in some Asian medicines and cosmetics. Public Health (1979) 1.42

Nanoparticles in drug delivery. Crit Rev Ther Drug Carrier Syst (1987) 1.42

Physicochemical properties of parenteral fat emulsions containing 20% triglyceride; Intralipid and Ivelip. J Clin Pharm Ther (1993) 1.40

Automated conductimetric titrimeter: use in studying ionic solute-solute interactions. J Pharm Sci (1975) 1.39

Surface modification of poly(lactide-co-glycolide) nanospheres by biodegradable poly(lactide)-poly(ethylene glycol) copolymers. Pharm Res (1994) 1.37

Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res (1994) 1.30

Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm (1999) 1.30

Biodegradable microparticles as controlled release antigen delivery systems. Immunology (1991) 1.24

Innovations in avoiding particle clearance from blood by Kupffer cells: cause for reflection. Crit Rev Ther Drug Carrier Syst (1994) 1.21

Gamma scintigraphy in the evaluation of pharmaceutical dosage forms. Eur J Nucl Med (1992) 1.20

Chitosan microspheres prepared by spray drying. Int J Pharm (1999) 1.20

Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. J Control Release (2001) 1.20

Microparticles as potentially orally active immunological adjuvants. Vaccine (1989) 1.19

Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology (1992) 1.19

The polyoxyethylene/polyoxypropylene block co-polymer poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. FEBS Lett (1992) 1.17

Secondary hypogonadism in older men: its relation to impotence. J Clin Endocrinol Metab (1990) 1.16

Incidence and prevalence of copper deficiency following roux-en-y gastric bypass surgery. Int J Obes (Lond) (2011) 1.14

Compliance in medication by Asian immigrants. Nurs Times (1979) 1.13

Lead poisoning and traditional practices: the consequences for world health. A study in Kuwait. Public Health (1981) 1.13

Transport of nanoparticles across the rat nasal mucosa. J Drug Target (2001) 1.11

Morphine kinetics after diamorphine infusion in premature neonates. Br J Clin Pharmacol (1991) 1.09

Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products? Int J Pharm (2000) 1.09

Preparation of biodegradable, surface engineered PLGA nanospheres with enhanced lymphatic drainage and lymph node uptake. Pharm Res (1997) 1.08

Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. Biochim Biophys Acta (1993) 1.08

Polylactide-poly(ethylene glycol) micellar-like particles as potential drug carriers: production, colloidal properties and biological performance. J Drug Target (2001) 1.07

Preparation of sub-100 nm human serum albumin nanospheres using a pH-coacervation method. J Drug Target (1993) 1.07

Epi-fluorescence microscopy and image analysis used to measure diffusion coefficients in gel systems. J Pharm Pharmacol (1992) 1.06

Controlled release microparticles for vaccine development. Vaccine (1991) 1.06

Defining the drug incorporation properties of PLA-PEG nanoparticles. Int J Pharm (2000) 1.06

A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine (2000) 1.04

The role of gamma-scintigraphy in oral drug delivery. Adv Drug Deliv Rev (2001) 1.04

An investigation of the filtration capacity and the fate of large filtered sterically-stabilized microspheres in rat spleen. Biochim Biophys Acta (1993) 1.04

Preparation and evaluation of biodegradable polymeric systems for the intra-articular delivery of drugs. J Pharm Pharmacol (1984) 1.03

Polystyrene-poly (ethylene glycol) (PS-PEG2000) particles as model systems for site specific drug delivery. 2. The effect of PEG surface density on the in vitro cell interaction and in vivo biodistribution. Pharm Res (1994) 1.02

Techniques for the measurement of the rheological properties of sputum. Bull Physiopathol Respir (Nancy) (1973) 1.02

Diamorphine infusion in the preterm neonate. Arch Dis Child (1991) 1.02

Targeting of drugs and vaccines to the gut. Pharmacol Ther (1995) 1.02

The organ uptake of intravenously administered colloidal particles can be altered using a non-ionic surfactant (Poloxamer 338). FEBS Lett (1984) 1.00

Intranasal delivery of morphine. J Pharmacol Exp Ther (2002) 0.99

Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable PLG microparticles. Vaccine (1995) 0.98

Structure and mucoadhesion of mussel glue protein in dilute solution. Biochemistry (1998) 0.98

The control of protein release from poly(DL-lactide co-glycolide) microparticles by variation of the external aqueous phase surfactant in the water-in oil-in water method. J Control Release (1998) 0.97

Spreading and retention of vaginal formulations in post-menopausal women as assessed by gamma scintigraphy. Pharm Res (1997) 0.97

Sustained release chitosan microspheres prepared by novel spray drying methods. J Microencapsul (1999) 0.97

Scientific principles in design of drug dosage formulations. Br Med J (1972) 0.96

Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates. J Med Chem (1996) 0.96

Sugar cross-linked gelatin for controlled release: microspheres and disks. Biomaterials (1998) 0.96

Physical properties and stability of two emulsion formulations of propofol. Int J Pharm (2001) 0.95

Bioadhesive starch microspheres and absorption enhancing agents act synergistically to enhance the nasal absorption of polypeptides. Int J Pharm (2001) 0.95

The use of scintigraphy to provide "proof of concept" for novel polysaccharide preparations designed for colonic drug delivery. Pharm Res (1997) 0.94

The in-vivo evaluation of an osmotic device (Osmet) using gamma scintigraphy. J Pharm Pharmacol (1984) 0.93

In vivo evaluation of enteric-coated naproxen tablets using gamma scintigraphy. Pharm Res (1992) 0.93

Toxicity of solubilized and colloidal amphotericin B formulations to human erythrocytes. J Pharm Pharmacol (1988) 0.93

Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes. FEBS Lett (1994) 0.92

Characterization of colonic transit of nondisintegrating tablets in healthy subjects. Dig Dis Sci (1993) 0.92

The rheological properties of sputum. Biorheology (1969) 0.92

The stability and immunogenicity of a protein antigen encapsulated in biodegradable microparticles based on blends of lactide polymers and polyethylene glycol. Vaccine (1999) 0.92

Detection and determination of surface levels of poloxamer and PVA surfactant on biodegradable nanospheres using SSIMS and XPS. J Control Release (1999) 0.92

Preparation of surface-modified albumin nanospheres. Biomaterials (1997) 0.91

Transdermal delivery of theophylline to premature infants using a hydrogel disc system. Br J Clin Pharmacol (1990) 0.91

Impotence and aging: clinical and hormonal factors. J Am Geriatr Soc (1988) 0.91

Preparation and characterisation of rose Bengal-loaded surface-modified albumin nanoparticles. J Control Release (2001) 0.91

The effect of the nasal cycle on mucociliary clearance. Clin Otolaryngol Allied Sci (2001) 0.90

The distribution of an intranasal insulin formulation in healthy volunteers: effect of different administration techniques. J Pharm Pharmacol (1994) 0.90

Effect of altered gastric emptying and gastrointestinal motility on metformin absorption. Br J Clin Pharmacol (2000) 0.89

The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer--poloxamine 908. Life Sci (1987) 0.89

Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine (1998) 0.89

Albumin microspheres for intra-articular drug delivery: investigation of their retention in normal and arthritic knee joints of rabbits. J Pharm Pharmacol (1987) 0.89

Clearance characteristics of chitosan based formulations in the sheep nasal cavity. Int J Pharm (2001) 0.89

Colonic delivery of dexamethasone: a pharmacoscintigraphic evaluation. Aliment Pharmacol Ther (1997) 0.88

Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine (1993) 0.88

Lymph node localisation of biodegradable nanospheres surface modified with poloxamer and poloxamine block co-polymers. FEBS Lett (1997) 0.88

Effect of the nonionic surfactant poloxamer 338 on the fate and deposition of polystyrene microspheres following intravenous administration. J Pharm Sci (1983) 0.88

Atomic force microscopy of gastric mucin and chitosan mucoadhesive systems. Biochem J (2000) 0.88

Morphology of Golgi-impregnated neurons in hyperstriatum ventralis, pars caudalis in adult male and female canaries. J Comp Neurol (1989) 0.87

In vitro cytotoxicity of poly(amidoamine)s: relevance to DNA delivery. Biochim Biophys Acta (1999) 0.87

Microviscosity and drug release from topical gel formulations. Pharm Res (1986) 0.87

Targeting of colloidal particles to the bone marrow. Life Sci (1987) 0.87

Nasal vaccination: a non-invasive vaccine delivery method that holds great promise for the future. Adv Drug Deliv Rev (2001) 0.87

An in vitro study of diamorphine permeation through premature human neonatal skin. Pharm Res (1993) 0.87

Preparation of sterically stabilized human serum albumin nanospheres using a novel Dextranox-MPEG crosslinking agent. Pharm Res (1994) 0.87

Development of a novel nasal nicotine formulation comprising an optimal pulsatile and sustained plasma nicotine profile for smoking cessation. J Control Release (2002) 0.87

Distribution and clearance of bioadhesive formulations from the olfactory region in man: effect of polymer type and nasal delivery device. Eur J Pharm Sci (2006) 0.87

Toxicity of amphotericin B emulsion formulations. J Antimicrob Chemother (1993) 0.86

Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. Vaccine (2003) 0.86

The effect of oils on the lymphatic absorption of DDT. J Pharm Pharmacol (1982) 0.86

Poly(butyl-2-cyanoacrylate) particles as adjuvants for oral immunization. Vaccine (1989) 0.86

Polymeric lamellar substrate particles for intranasal vaccination. Adv Drug Deliv Rev (2001) 0.86

Do recurrences after paraesophageal hernia repair matter? : Ten-year follow-up after laparoscopic repair. Surg Endosc (2007) 0.86

Determination of thermodynamics of the methylene group in solutions of drug molecules. J Pharm Pharmacol (1972) 0.85

Development of systems for targeting the regional lymph nodes for diagnostic imaging: in vivo behaviour of colloidal PEG-coated magnetite nanospheres in the rat following interstitial administration. Pharm Res (2001) 0.85